A new paradigm evaluating cost per cure of HCV infection in the UK

BACKGROUND: New interferon (IFN)-free treatments for hepatitis C are more effective, safer but more expensive than current IFN-based therapies. Comparative data of these, versus current first generation protease inhibitors (PI) with regard to costs and treatment outcomes are needed. We investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Barclay, Stephen T., Cooke, Graham S., Holtham, Elizabeth, Gauthier, Aline, Schwarzbard, Jeremie, Atanasov, Petar, Irving, William L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898515/
https://www.ncbi.nlm.nih.gov/pubmed/30288304
http://dx.doi.org/10.1186/s41124-016-0002-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898515/
https://www.ncbi.nlm.nih.gov/pubmed/30288304
http://dx.doi.org/10.1186/s41124-016-0002-z

Ejemplares similares